Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 9:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 205 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Low-Molecular-Weight Heparin Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects

NCT02271113
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GMI-1271, Placebo, Enoxaparin Sodium (Lovenox®)
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 3, 2026, 9:00 PM EDT
Terminated Not applicable Interventional Results available

Enoxaparin and/or Minocycline in Acute Stroke

NCT00836355
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Enoxaparin, Minocycline
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 95 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2016 · Synced Oct 3, 2026, 9:00 PM EDT
Terminated Phase 3 Interventional Results available

Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

NCT00522392
View directory record Official record
Conditions
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
bortezomib, lenalidomide, dexamethasone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
275
States / cities
Scottsdale, Arizona • Fairfield, California • San Diego, California + 184 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

NCT00790335
View directory record Official record
Conditions
Deep Vein Thrombosis, Venous Thrombosis, Postphlebitic Syndrome, Venous Thromboembolism, Post Thrombotic Syndrome
Interventions
Recombinant tissue plasminogen activator (rt-PA)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
16 Years to 75 Years
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
56
States / cities
Glendale, Arizona • Orange, California • Stanford, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 2Phase 3 Interventional

Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)

NCT04372589
View directory record Official record
Conditions
COVID-19, Pneumonia
Interventions
Heparin
Drug
Lead sponsor
University of Manitoba
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Atlanta, Georgia • Chicago, Illinois • Jefferson, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 3, 2026, 9:00 PM EDT
Completed No phase listed Observational

Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims Data

NCT05083455
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolus
Interventions
Rivaroxaban, Enoxaparin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
89,215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 2Phase 3 Interventional

BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery

NCT00097357
View directory record Official record
Conditions
Venous Thrombosis, Pulmonary Embolism
Interventions
Apixaban, Enoxaparin, Warfarin, Enoxaparin Placebo, Apixaban Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
72
States / cities
Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 2 Interventional

Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)

NCT04640181
View directory record Official record
Conditions
Covid19
Interventions
Enoxaparin, Rivaroxaban
Drug
Lead sponsor
St. David's HealthCare
Other
Eligibility
18 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 3, 2026, 9:00 PM EDT
Terminated Phase 4 Interventional Results available

Below Knee DVT Study

NCT03805672
View directory record Official record
Conditions
Deep Vein Thrombosis (DVT), Blood Clots
Interventions
Low Dose Enoxaparin, High Dose Enoxaparin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 3, 2026, 9:00 PM EDT
Recruiting Phase 4 Interventional

Apixaban or Enoxaparin After Head and Neck Cancer Surgery

NCT07189897
View directory record Official record
Conditions
Venous Thromboembolism, Head and Neck Cancer
Interventions
Enoxaparin, Apixaban
Drug
Lead sponsor
Kiranya Arnold
Other
Eligibility
18 Years to 89 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 3, 2026, 9:00 PM EDT
Completed No phase listed Observational Results available

A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer

NCT05643885
View directory record Official record
Conditions
Thromboembolism
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
7,304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 2 Interventional Results available

A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery

NCT00398216
View directory record Official record
Conditions
Thrombosis, Hip Replacement
Interventions
DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
903 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Hartford, Connecticut • Sarasota, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness

NCT00457002
View directory record Official record
Conditions
Venous Thrombosis, Pulmonary Embolism
Interventions
Apixaban, Enoxaparin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
40 Years and older
Enrollment
6,758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
48
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Early Phase 1 Interventional

Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin

NCT03516656
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
Interventions
Standard heparin dose, Real time heparin dose adjustment
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study

NCT01747746
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Thrombo-embolism, Bleeding
Interventions
Rivaroxaban, Warfarin and Enoxaparin
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 3 Interventional

TIPPS: Thrombophilia in Pregnancy Prophylaxis Study

NCT00967382
View directory record Official record
Conditions
Pregnancy, Thrombophilia, Pregnancy Complications
Interventions
dalteparin sodium
Drug
Lead sponsor
Ottawa Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
2
States / cities
St Louis, Missouri • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 1 Interventional

Twice Daily Enoxaparin Prophylaxis in Reconstructive Surgery Patients

NCT02687204
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolus
Interventions
Twice daily enoxaparin prophylaxis, Real time dose adjustment
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 2 Interventional Results available

Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients

NCT02706249
View directory record Official record
Conditions
Venous Thormboembolism
Interventions
Enoxaparin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 3, 2026, 9:00 PM EDT
Terminated Phase 4 Interventional Results available

Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin

NCT03296033
View directory record Official record
Conditions
Anticoagulants and Bleeding Disorders, Surgery, Regional Anesthesia Morbidity
Interventions
Enoxaparin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 100 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Not applicable Interventional Results available

Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)

NCT00358735
View directory record Official record
Conditions
Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE), Bleeding
Interventions
ActiveCare CECT device, Enoxaparin
Device · Drug
Lead sponsor
Medical Compression Systems
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
La Jolla, California • Loma Linda, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Oct 3, 2026, 9:00 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Low-Molecular-Weight Heparin (LMWH) for Deep Venous Thrombosis (DVT) Prophylaxis

NCT01029821
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Low-Molecular-Weight Heparin
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

NCT00643201
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Enoxaparin, warfarin, Placebo for apixaban, Placebo for enoxaparin, Placebo for warfarin, apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5,614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
73
States / cities
Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 3, 2026, 9:00 PM EDT
Completed No phase listed Observational

Heparin or Enoxaparin in Patients With Cancer

NCT00004875
View directory record Official record
Conditions
Lymphoma, Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
enoxaparin, heparin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 21, 2011 · Synced Oct 3, 2026, 9:00 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery

NCT06118957
View directory record Official record
Conditions
Thromboembolism
Interventions
Enoxaparin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 3, 2026, 9:00 PM EDT